Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status

JAMA Oncol. 2015 Jul;1(4):427-8. doi: 10.1001/jamaoncol.2015.1237.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antineoplastic Agents / administration & dosage*
  • Biomarkers, Tumor / antagonists & inhibitors*
  • Biomarkers, Tumor / genetics*
  • Female
  • Humans
  • Male
  • Melanoma / drug therapy*
  • Mutation*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / genetics*
  • Skin Neoplasms / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Programmed Cell Death 1 Receptor
  • Proto-Oncogene Proteins B-raf